Valneva and pfizer report further positive phase 2 data for lyme disease vaccine candidate

Saint-herblain (france) and new york, february 4, 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, and pfizer inc. (nyse: pfe) today reported further positive phase 2 data for their lyme disease vaccine candidate, vla15. based on these new results, valneva and pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned phase 3 clinical trial. the trial will evaluate vla15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in 2022, subject to regulatory approval.
VALN Ratings Summary
VALN Quant Ranking